SEC Form N-PORT · 2026-03-31
FTXH ETF Holdings
First Trust Nasdaq Pharmaceuticals ETF reported 51 holdings. Weights reproduce the source and may not sum to exactly 100 because of cash, derivatives, rounding, liabilities, or other positions.
- Report date
- 2026-03-31
- SEC accession
- 0000940400-26-020386
- Series ID
- S000053945
- Source
- SEC Form N-PORT
All reported holdings
| Ticker | Issuer | Weight | Value (USD) | Balance |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 7.450831% | 2,173,804.92 | 8,893 NS |
| BMY | Bristol-Myers Squibb Company | 7.363563% | 2,148,344.3 | 35,422 NS |
| MRK | Merck & Co., Inc | 7.356675% | 2,146,334.47 | 17,843 NS |
| ABBV | AbbVie Inc. | 7.096764% | 2,070,504.8 | 9,520 NS |
| LLY | Eli Lilly & Co. | 6.620376% | 1,931,517 | 2,100 NS |
| PFE | Pfizer Inc. | 3.845111% | 1,121,824.08 | 39,951 NS |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.741998% | 1,091,740.32 | 1,413 NS |
| BIIB | Biogen Inc | 3.618802% | 1,055,797.47 | 5,759 NS |
| GILD | Gilead Sciences Inc. | 3.542609% | 1,033,567.92 | 7,416 NS |
| CAH | Cardinal Health, Inc. | 3.490287% | 1,018,302.89 | 4,819 NS |
| AMGN | Amgen Inc. | 3.432232% | 1,001,365.1 | 2,846 NS |
| VTRS | Viatris Inc | 3.426152% | 999,591.39 | 73,989 NS |
| ZTS | Zoetis Inc. | 3.413971% | 996,037.46 | 8,426 NS |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.402389% | 992,658.42 | 2,223 NS |
| UTHR | United Therapeutics Corporation | 3.312926% | 966,557.4 | 1,630 NS |
| INCY | Incyte Corporation. | 2.20756% | 644,063.16 | 6,843 NS |
| JAZZ | Jazz Pharmaceuticals PLC | 2.168785% | 632,750.35 | 3,347 NS |
| ILMN | Illumina Inc | 1.54501% | 450,761.82 | 3,657 NS |
| EXEL | Exelixis, Inc. | 1.511093% | 440,866.31 | 10,279 NS |
| MEDP | Medpace Holdings Inc. | 1.423683% | 415,364.35 | 865 NS |
| PTCT | PTC Therapeutics, Inc. | 1.272446% | 371,240.37 | 5,449 NS |
| CRL | Charles River Laboratories International, Inc. | 1.257595% | 366,907.5 | 2,127 NS |
| BMRN | Biomarin Pharmaceutical Inc. | 1.223307% | 356,903.82 | 6,318 NS |
| NBIX | Neurocrine Biosciences Inc | 1.187565% | 346,476.2 | 2,630 NS |
| HALO | Halozyme Therapeutics Inc | 1.108721% | 323,473.15 | 5,005 NS |
| ALKS | Alkermes PLC | 1.015641% | 296,316.8 | 8,380 NS |
| ELAN | Elanco Animal Health Inc | 0.896083% | 261,435.25 | 10,925 NS |
| SYRE | Spyre Therapeutics Inc | 0.610805% | 178,204.52 | 3,533 NS |
| PTGX | Protagonist Therapeutics Inc | 0.596086% | 173,910 | 1,650 NS |
| TGTX | TG Therapeutics Inc | 0.574896% | 167,727.78 | 5,049 NS |
| ARWR | Arrowhead Pharmaceuticals Inc | 0.561124% | 163,709.7 | 2,611 NS |
| CPRX | Catalyst Pharmaceuticals Inc. | 0.558674% | 162,995.08 | 6,583 NS |
| AMRX | Amneal Pharmaceuticals Inc | 0.553177% | 161,391.12 | 12,984 NS |
| RCUS | ARCUS BIOSCIENCES INC | 0.552228% | 161,114.4 | 7,459 NS |
| TWST | Twist Bioscience Corporation | 0.527397% | 153,869.76 | 3,238 NS |
| LGND | Ligand Pharmaceuticals Incorporated | 0.524182% | 152,931.9 | 766 NS |
| MIRM | Mirum Pharmaceuticals Inc. | 0.521185% | 152,057.48 | 1,646 NS |
| TVTX | Travere Therapeutics Inc | 0.519346% | 151,521 | 5,100 NS |
| ALNY | Alnylam Pharmaceuticals Inc. | 0.517138% | 150,876.72 | 456 NS |
| GH | Guardant Health Inc | 0.512264% | 149,454.66 | 1,618 NS |
| ROIV | Roivant Sciences Ltd | 0.498452% | 145,425 | 5,250 NS |
| MRNA | Moderna Inc | 0.493803% | 144,068.8 | 2,836 NS |
| SUPN | Supernus Pharmaceuticals, Inc | 0.491824% | 143,491.44 | 2,776 NS |
| KRYS | Krystal Biotech Inc | 0.487858% | 142,334.32 | 551 NS |
| TARS | Tarsus Pharmaceuticals Inc | 0.483771% | 141,141.8 | 2,012 NS |
| IONS | Ionis Pharmaceuticals, Inc. | 0.481806% | 140,568.48 | 1,872 NS |
| TXG | 10X Genomics Inc | 0.479607% | 139,926.93 | 6,591 NS |
| KYMR | Kymera Therapeutics Inc | 0.474755% | 138,511.27 | 1,663 NS |
| ACAD | Acadia Pharmaceuticals Inc | 0.471975% | 137,700.36 | 6,186 NS |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | 0.454882% | 132,713.48 | 5,633 NS |
| MISXX | Dreyfus Government Cash Management Funds | 0.110692% | 32,294.83 | 32,294.83 NS |